IGF-1 LR3: Strong Pharmacology, Zero Human Trials

At a Glance

IGF-1 LR3 is the clearest example in this library of a compound whose reputation runs far ahead of its evidence. The molecule is real, well characterised biochemically, and genuinely more potent than native IGF-1 in animals. What it does not have, and has never had, is a human study. Not a phase 1, not a dose-finding study, not a case series with laboratory follow-up.

The honest verdict: IGF-1 LR3 is pharmacologically plausible and clinically unknown. Everything written about its effects on muscle in people is extrapolation from three sources: rodent anabolism experiments from the early 1990s, the known biology of the IGF-1 receptor, and clinical experience with recombinant native IGF-1 in children with severe IGF-1 deficiency. That third source is the most useful, because it shows what happens when humans are given a molecule that activates this receptor: they grow, and nearly half get hypoglycaemia.

Two risks deserve to be stated before anything else. The acute one is low blood sugar. The chronic one is that IGF-1 receptor activation is the same signal cancer biology spends its time studying, and the epidemiology linking higher IGF-1 to prostate and premenopausal breast cancer is not reassuring.

How it works

Native IGF-1 circulates almost entirely bound to IGF binding proteins, chiefly IGFBP-3 in a ternary complex with acid-labile subunit. Less than 1% is free. That system exists to buffer a growth factor that would otherwise behave like insulin.

IGF-1 LR3 was engineered to defeat that buffer. The design work described a family of fusion analogues in which glutamic acid at position 3 was replaced by glycine or arginine and a hydrophobic N-terminal extension was added, and showed that reduced binding-protein affinity rather than better receptor binding explained the increased potency (Francis 1992).

The functional consequence was measured in a catabolic rat model. Dexamethasone-treated rats given IGF-1 or its analogues by osmotic pump showed dose-dependent gains in body weight and nitrogen retention; des(1-3)IGF-1 and LR3-IGF-1 were about 2.5-fold more potent than native IGF-1. Notably, LR3-IGF-1 achieved that while binding the type 1 IGF receptor about threefold less well than native IGF-1, which the authors attributed to escaping the binding proteins that dexamethasone had raised (Tomas 1992).

Downstream, the receptor does what it always does. IGF-1R is a tyrosine kinase that recruits IRS-1 and activates PI3K-Akt-mTOR, driving protein synthesis and suppressing breakdown, plus MAPK/ERK, driving proliferation and survival. The current review of this compound class notes that IGF-1 LR3 is presumed to reproduce native IGF-1 signalling, that its altered binding characteristics may change the magnitude and time course, and that no human interventional data exist to check this (Dominikowski 2026).

Two practical implications follow:

• Long exposure. Escaping the binding proteins and clearing slowly means a long effective duration, which is why protocols dose once daily rather than several times.
• No localisation. A molecule with that kind of systemic persistence is not confined to the muscle it was injected into. Clearance and distribution studies of labelled LR3-IGF-1 in rodents show movement from blood into extravascular sites generally (Bastian 2000).

What the evidence shows

Human data: none for IGF-1 LR3, some for native IGF-1

There is no human study of IGF-1 LR3. The closest relevant human evidence is recombinant native IGF-1 (mecasermin), an approved drug:

• Efficacy and adverse events. 76 children with severe IGF-1 deficiency due to GH insensitivity received recombinant human IGF-1 at 60-120 mcg/kg twice daily for up to 12 years. Height velocity rose from 2.8 to 8.0 cm/year in the first year and stayed above baseline for up to eight years. The most common adverse event was hypoglycaemia, reported by 49% of treated subjects (Chernausek 2007).
• PEGylated IGF-1 in healthy adults. A first-in-man study of a PEGylated recombinant human IGF-1 in 62 healthy volunteers found a half-life of 140-200 hours, dose-proportional exposure, injection-site erythema as the most frequent adverse event, no hypoglycaemia at the doses tested, and near-complete suppression of GH secretion through feedback (Kletzl 2017). That last point matters for anyone combining an IGF-1 analogue with a GH secretagogue: exogenous IGF-1 shuts the GH axis down.

Why extrapolation is limited. Even in clinical populations, interventional IGF-1 evidence for skeletal muscle gain is thin, and trials combining IGF-1 with IGFBP-3 in neuromuscular disease did not deliver the hoped-for functional benefit (Dominikowski 2026).

Animal and laboratory data, labelled as such

• Analogue design and the binding-protein mechanism (Francis 1992).
• Anabolic potency about 2.5-fold that of native IGF-1 in dexamethasone-treated rats (Tomas 1992).
• Altered plasma clearance in renal failure models, showing how dependent IGF-1 kinetics are on binding-protein status (Gillespie 1996).
• Transport from blood into extravascular wound-fluid sites (Bastian 2000).

Risk data worth knowing

A meta-regression of 21 studies with 3,609 cases and 7,137 controls found that high circulating IGF-1 was associated with increased risk of prostate cancer (odds ratio 1.49 comparing the 75th with the 25th percentile) and premenopausal breast cancer (1.65) (Renehan 2004). That is an association with endogenous IGF-1, not a measurement of risk from injecting an analogue, and it is the single most important piece of context for this compound.

Product quality, specifically measured

An anti-doping method-development study analysed black-market IGF-1 analogue products and found abundant lower-quality, oxidised peptide forms, which is why the method had to monitor both native and mono-oxidised forms (Mongongu 2021). That is a direct laboratory finding about products in circulation, not a general warning.

Dosing

For informational purposes only — this summarises doses used in research and practice; it is not a prescription or individual medical advice.

No human trial dose exists for IGF-1 LR3. The first two rows below are the nearest human reference points, for a different molecule.

Titration as it is actually done. Protocols start at 20 mcg daily and increase only if there are no hypoglycaemic symptoms. Doses are taken with carbohydrate, and fast-acting glucose is kept to hand. The convention of 4 to 6 weeks on and an equal period off comes from a concern about receptor downregulation; it has not been tested in any species.

What the dose numbers are not. They are not weight-based, unlike every animal and clinical IGF-1 study, and they did not come from a dose-finding process. They are a community convention. The spread between 20 mcg and 100 mcg daily is a fivefold range with no data to adjudicate it, and the review that catalogued these patterns labels them explicitly as behavioural data rather than clinical recommendations (Dominikowski 2026).

Reconstitution and technique are in the peptide injection guide.

What people report: what works and what doesn’t

Sources: the aggregated community data sets (Peptide Protocol Wiki, 80 reports; Peptide DB), the protocol and adverse-effect patterns in the peer-reviewed review (Dominikowski 2026), and the clinical data on native IGF-1. Patterns, not proof.

Reported to work

• Hypoglycaemic symptoms at higher doses. The most consistent and most verifiable report: shakiness, sweating, hunger and light-headedness within hours. It confirms the molecule is biologically active, and it is the thing people most often underestimate.
• A noticeable pump and fullness in trained muscle during a cycle, usually described in the first two weeks.
• Faster recovery between sessions, commonly described, almost always within a stack.

Mixed or unclear

• Lean mass gain. Reports range from clear to nothing. Cycles are short, almost always combined with other compounds, and never accompanied by body-composition imaging.
• Local growth from injecting a specific muscle. Widely practised, pharmacologically unlikely, unverified. The long duration and systemic distribution argue against it.
• Whether short cycles are necessary. Universal in practice, untested anywhere.
• Product authenticity. Reports of “nothing happened” are impossible to separate from product problems, and black-market IGF-1 analogue material has been shown analytically to contain oxidised, degraded forms (Mongongu 2021).

Reported not to work, or disappointing

• Dramatic results. The gap between expectation and outcome is wider here than for almost any peptide, probably because the animal potency figures get quoted without the species attached.
• Side effects people stop for: hypoglycaemia, headaches, jaw or joint ache, oedema and fatigue. Some report numbness or tingling similar to GH-related fluid shifts.
• Combining it with GH. Reported as underwhelming by some, which is mechanistically interesting: exogenous IGF-1 suppresses pituitary GH release through negative feedback, so the two partly cancel (Kletzl 2017).

What a properly designed trial would need to show: a phase 1 dose-finding study with glucose monitoring, then a randomised placebo-controlled trial of at least 12 weeks measuring lean mass by DXA or MRI, strength, glucose tolerance, and IGF-1 and IGFBP-3 kinetics. None of that exists.

Safety and side effects

Hypoglycaemia is the headline risk. IGF-1 and its analogues have insulin-like activity. In the long-term native rhIGF-1 study, 49% of children reported hypoglycaemia (Chernausek 2007). Mecasermin’s label instructs that doses be taken with a meal or snack for exactly this reason. An analogue engineered to stay free in circulation longer is not obviously safer on this axis.

GH axis suppression. PEGylated rhIGF-1 almost completely suppressed GH secretion in healthy volunteers (Kletzl 2017). Expect the same direction of effect, which has implications for anyone stopping abruptly after weeks of exogenous IGF-1.

Mitogenic concern. IGF-1R signalling is a canonical proliferation and survival pathway, and high circulating IGF-1 associates with prostate and premenopausal breast cancer risk (Renehan 2004). Active or prior malignancy should be treated as a contraindication. Mecasermin’s own label carries neoplasia warnings and advises against use with active or suspected malignancy.

Known adverse effects from the native-molecule class: hypoglycaemia, tonsillar and adenoidal hypertrophy, injection-site lipohypertrophy, headache, raised intracranial pressure, and in paediatric use, slipped capital femoral epiphysis and scoliosis progression.

Entirely unknown for IGF-1 LR3: immunogenicity in humans, long-term organ effects, retinal or renal effects, use in pregnancy or lactation, interaction with insulin or sulfonylureas (expect additive hypoglycaemia), and interaction with GLP-1 agonists.

Product risk. No pharmaceutical-grade IGF-1 LR3 exists. The material in circulation is research reagent or grey-market synthesis, and the one analytical study that looked specifically at black-market IGF-1 analogues found oxidised degradation products as a routine feature (Mongongu 2021). See peptide sourcing and peptide safety.

Legal and regulatory status

United States. IGF-1 LR3 has never been submitted for human use and is sold as a research reagent. It does not appear in category 1 or 2 of FDA’s 503A bulk drug substance list (updated 14 May 2026), and absence from those lists is not authorisation: a bulk substance may be used in 503A compounding only if it meets a statutory condition, which an unapproved research analogue does not. Native recombinant IGF-1 is a different matter, since mecasermin (Increlex) is an approved prescription drug for severe primary IGF-1 deficiency. See are peptides legal.

European Union and Germany. No authorisation for IGF-1 LR3. Germany’s Anti-Doping Act (AntiDopG) annex lists mecasermin, “IGF-1 Analoga” and mechano growth factor among growth factors and growth-factor modulators. Under § 2(3), acquiring, possessing or importing more than a “non-small quantity” for the purpose of doping in sport is an offence, and the quantity regulation (DmMV, in force 16 March 2023) sets that threshold at 3 mg for IGF-1 analogues, against 60 mg for mecasermin itself. Three milligrams is a small number of typical vials.

Sport. Prohibited at all times under section S2 of the WADA list, which names IGF-1 and its analogues. Anti-doping laboratories have validated immunopurification and high-resolution mass spectrometry methods specifically for LongR3-IGF-1, des(1-3)-IGF-1 and R3-IGF-1 (Mongongu 2021). See peptides and anti-doping rules.

How IGF-1 LR3 fits

The comparison that matters most is with the GH secretagogues one shelf over. Those raise IGF-1 indirectly, inside a feedback loop that limits how high it can go. IGF-1 LR3 bypasses the loop entirely, which is why it appeals to people chasing an anabolic signal and why it is the compound I would be most cautious about in this batch. Peptides for muscle growth sets out the realistic hierarchy, and for people whose actual goal is preserving muscle during weight loss, the activin-receptor and GLP-1 literature in Bimagrumab and semaglutide is a better-evidenced place to look.

What I would want before considering this seriously is a phase 1 study. Not a protocol, not a potency figure from a 1992 rat experiment.

Related Articles

• Peptides for Muscle Growth: What the Evidence Actually Supports — where growth factors sit against resistance training and protein.
• MGF (Mechano Growth Factor): The IGF-1 Splice Variant — the local IGF-1 isoform people pair with this.
• PEG-MGF: PEGylation Without Human Data — the long-acting version, and what FDA says about it.
• Peptide Safety: What You Need to Know — monitoring and risk framework.
• Peptide Therapy for Athletes: What’s Banned Under WADA Rules in 2026 — detection methods for IGF-1 analogues.